LONDON (Reuters) ? Three organizations will fight it out to take over the London Olympic press and broadcast centre after this year's Games with a fashion college among the ideas being put forward, the Olympic Park Legacy Company said on Thursday.
UK Fashion Hub, Oxylane Group and iCITY have been selected from 10 bidders to enter into detailed negotiations to take up tenancy of the building, which offers about 1 million square foot of commercial space, from early 2013.
"We have three dynamic bids focused on the creation of thousands of jobs and training opportunities," said Andrew Altman, chief executive of the Olympic Park Legacy Company.
UK Fashion Hub envisages a fashion and textile manufacturing centre with a fashion college while Oxylane Group would offer a leisure facility, a retail store and a technology centre.
iCITY plans an "Innovation City" featuring a cloud computing centre and a technology research base.
(Reporting by Michael Holden, editing by Mark Meadows)
Study finds that tumor cells can prevent cancer spreadPublic release date: 17-Jan-2012 [ | E-mail | Share ]
Contact: Bonnie Prescott bprescot@bidmc.harvard.edu 617-667-7306 Beth Israel Deaconess Medical Center
Paradoxical discovery finds that a group of cells known as pericytes help prevent metastasis
BOSTON A new study finds that a group of little-explored cells in the tumor microenvironment likely serve as important gatekeepers against cancer progression and metastasis. Published in the January 17 issue of Cancer Cell, these findings suggest that anti-angiogenic therapies which shrink cancer by cutting off tumors' blood supply may inadvertently be making tumors more aggressive and likely to spread.
One approach to treating cancer targets angiogenesis, or blood vessel growth. In this new investigation, senior author Raghu Kalluri, MD, PhD, Chief of the Division of Matrix Biology at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical School (HMS), wanted to find out if targeting a specific cell type, the pericyte, could inhibit tumor growth in the same way that other antiangiogenic drugs do. Pericytes are an important part of tissue vasculature, covering blood vessels and supporting their growth.
Kalluri and his colleagues began by creating mice genetically engineered to support drug-induced depletion of pericytes in growing tumors. They then deleted pericytes in implanted mouse breast cancer tumors, decreasing pericyte numbers by 60 percent. Compared with wild-type controls, they saw a 30 percent decrease in tumor volumes over 25 days. However, contrary to conventional clinical wisdom, the investigators found that the number of secondary lung tumors in the engineered mice had increased threefold compared to the control mice, indicating that the tumors had metastasized.
"If you just looked at tumor growth, the results were good," says Kalluri. "But when you looked at the whole picture, inhibiting tumor vessels was not controlling cancer progression. The cancer was, in fact, spreading."
To understand the mechanism behind this increased metastasis, Kalluri and his team examined the tumor's microenvironment to find out what changes were taking place at the molecular level. They found a fivefold percentage increase in hypoxic areas in tumors lacking pericytes. "This suggested to us that without supportive pericytes, the vasculature inside the tumor was becoming weak and leakyeven more so than it already is inside most tumorsand this was reducing the flow of oxygen to the tumor," explains Kalluri.
"Cancer cells respond to hypoxia by launching genetic survival programs," he adds. To that end, the investigators found evidence of epithelial-to-mesenchymal transition (EMT), a change that makes the cells more mobile, so they can travel through those leaky vessels to new locations, and makes them behave more like stem cells, so they are better able to survive. Experiments that demonstrated fivefold increases in protein markers of EMT showed that the cells had undergone the change. The team also found a fivefold increase in activation of Met, a receptor molecule that promotes cell migration and growth.
Importantly, the team found that these molecular changes occurred inside the smaller, pericyte-depleted tumors that had increased incidences of secondary tumors in the lungs in the mouse models. "This suggested that smaller tumors are shedding more cancer cells into the blood and causing more metastasis," says Kalluri. "We showed that a big tumor with good pericyte coverage is less metastatic than a smaller tumor of the same type with less pericyte coverage."
Because cancer therapies such as Imatinib, Sunitinib and others have been shown to decrease pericytes in tumors, the researchers' next step was to perform the same experiments in mice with primary tumors, only this time, using Imatinib and Sunitinib rather than genetic programs to decrease pericyte numbers. And while both Imatinib and Sunitinib caused a 70 percent pericyte depletion, the end results, stayed the same: metastasis increased threefold. "We showed that a big tumor with good pericyte coverage is less metastatic than a smaller tumor of the same type with less pericyte coverage," says Kalluri, who corroborated these findings in multiple types of cancer by repeating these same experiments with implanted renal cell carcinoma and melanoma tumors.
Additional experiments showed that combining pericyte-depleting drugs with the Met-inhibiting drug helped suppress EMT and metastasis.
Finally, to determine if the findings were relevant to patients, the scientists examined 130 breast cancer tumor samples of varying cancer stages and tumor sizes and compared pericyte levels with prognosis. They found that samples with low numbers of pericytes in tumor vasculature and high levels of Met expression correlated with the most deeply invasive cancers, distant metastasis and 5- and 10- year survival rates lower than 20 percent.
"These results are quite provocative and will influence clinical programs designed to target tumor angiogenesis," says Ronald A. DePinho, president of the University of Texas MD Anderson Cancer Center. "These impressive studies will inform and refine potential therapeutic approaches for many cancers."
Meanwhile, for Kalluri, the work suggests that certain assumptions about cancer must be revisited. "We must go back and audit the tumor and find out which cells play a protective role versus which cells promote growth and aggression," says Kalluri. "Not everything is black and white. There are some cells inside a tumor that are actually good in certain contexts."
###
Collaborators in this study include BIDMC investigators Vesselina Cooke and Valerie LeBleu (co-first authors) Doruk Keskin, Zainab Khan, Joyce O'Connell, Yingqi Teng, Michael Duncan, Liang Xie, Genta Maeda, Sylvia Vong, and Hikaru Sugimoto. Additional investigators Rafael Rocha, Aline Damascena, and Ricardo Brentani collaborated from Hospital A. C. Camargo in the National Institute of Oncogenomics of Brazil.
This study was supported by the National Institutes of Health (NIH). Kalluri is a Champalimaud investigator funded by the Champalimaud metastasis programme. Cooke is funded by a Ruth Kirschstein Post-doctoral fellowship. LeBleu is funded by an NIH training grant in gastroenterology. Duncan is funded by an NIH training grant in cancer biology, an NIH supplemental grant to support diversity, and a United Negro College Fund-Merck Postdoctoral Science Research Fellowship. Sugimoto is funded by an NIH research training grant in cardiovascular medicine. O'Connell is funded by the Department of Defense Breast Cancer Predoctoral Traineeship Award.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is a clinical partner of the Joslin Diabetes Center and a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Study finds that tumor cells can prevent cancer spreadPublic release date: 17-Jan-2012 [ | E-mail | Share ]
Contact: Bonnie Prescott bprescot@bidmc.harvard.edu 617-667-7306 Beth Israel Deaconess Medical Center
Paradoxical discovery finds that a group of cells known as pericytes help prevent metastasis
BOSTON A new study finds that a group of little-explored cells in the tumor microenvironment likely serve as important gatekeepers against cancer progression and metastasis. Published in the January 17 issue of Cancer Cell, these findings suggest that anti-angiogenic therapies which shrink cancer by cutting off tumors' blood supply may inadvertently be making tumors more aggressive and likely to spread.
One approach to treating cancer targets angiogenesis, or blood vessel growth. In this new investigation, senior author Raghu Kalluri, MD, PhD, Chief of the Division of Matrix Biology at Beth Israel Deaconess Medical Center (BIDMC) and Professor of Medicine at Harvard Medical School (HMS), wanted to find out if targeting a specific cell type, the pericyte, could inhibit tumor growth in the same way that other antiangiogenic drugs do. Pericytes are an important part of tissue vasculature, covering blood vessels and supporting their growth.
Kalluri and his colleagues began by creating mice genetically engineered to support drug-induced depletion of pericytes in growing tumors. They then deleted pericytes in implanted mouse breast cancer tumors, decreasing pericyte numbers by 60 percent. Compared with wild-type controls, they saw a 30 percent decrease in tumor volumes over 25 days. However, contrary to conventional clinical wisdom, the investigators found that the number of secondary lung tumors in the engineered mice had increased threefold compared to the control mice, indicating that the tumors had metastasized.
"If you just looked at tumor growth, the results were good," says Kalluri. "But when you looked at the whole picture, inhibiting tumor vessels was not controlling cancer progression. The cancer was, in fact, spreading."
To understand the mechanism behind this increased metastasis, Kalluri and his team examined the tumor's microenvironment to find out what changes were taking place at the molecular level. They found a fivefold percentage increase in hypoxic areas in tumors lacking pericytes. "This suggested to us that without supportive pericytes, the vasculature inside the tumor was becoming weak and leakyeven more so than it already is inside most tumorsand this was reducing the flow of oxygen to the tumor," explains Kalluri.
"Cancer cells respond to hypoxia by launching genetic survival programs," he adds. To that end, the investigators found evidence of epithelial-to-mesenchymal transition (EMT), a change that makes the cells more mobile, so they can travel through those leaky vessels to new locations, and makes them behave more like stem cells, so they are better able to survive. Experiments that demonstrated fivefold increases in protein markers of EMT showed that the cells had undergone the change. The team also found a fivefold increase in activation of Met, a receptor molecule that promotes cell migration and growth.
Importantly, the team found that these molecular changes occurred inside the smaller, pericyte-depleted tumors that had increased incidences of secondary tumors in the lungs in the mouse models. "This suggested that smaller tumors are shedding more cancer cells into the blood and causing more metastasis," says Kalluri. "We showed that a big tumor with good pericyte coverage is less metastatic than a smaller tumor of the same type with less pericyte coverage."
Because cancer therapies such as Imatinib, Sunitinib and others have been shown to decrease pericytes in tumors, the researchers' next step was to perform the same experiments in mice with primary tumors, only this time, using Imatinib and Sunitinib rather than genetic programs to decrease pericyte numbers. And while both Imatinib and Sunitinib caused a 70 percent pericyte depletion, the end results, stayed the same: metastasis increased threefold. "We showed that a big tumor with good pericyte coverage is less metastatic than a smaller tumor of the same type with less pericyte coverage," says Kalluri, who corroborated these findings in multiple types of cancer by repeating these same experiments with implanted renal cell carcinoma and melanoma tumors.
Additional experiments showed that combining pericyte-depleting drugs with the Met-inhibiting drug helped suppress EMT and metastasis.
Finally, to determine if the findings were relevant to patients, the scientists examined 130 breast cancer tumor samples of varying cancer stages and tumor sizes and compared pericyte levels with prognosis. They found that samples with low numbers of pericytes in tumor vasculature and high levels of Met expression correlated with the most deeply invasive cancers, distant metastasis and 5- and 10- year survival rates lower than 20 percent.
"These results are quite provocative and will influence clinical programs designed to target tumor angiogenesis," says Ronald A. DePinho, president of the University of Texas MD Anderson Cancer Center. "These impressive studies will inform and refine potential therapeutic approaches for many cancers."
Meanwhile, for Kalluri, the work suggests that certain assumptions about cancer must be revisited. "We must go back and audit the tumor and find out which cells play a protective role versus which cells promote growth and aggression," says Kalluri. "Not everything is black and white. There are some cells inside a tumor that are actually good in certain contexts."
###
Collaborators in this study include BIDMC investigators Vesselina Cooke and Valerie LeBleu (co-first authors) Doruk Keskin, Zainab Khan, Joyce O'Connell, Yingqi Teng, Michael Duncan, Liang Xie, Genta Maeda, Sylvia Vong, and Hikaru Sugimoto. Additional investigators Rafael Rocha, Aline Damascena, and Ricardo Brentani collaborated from Hospital A. C. Camargo in the National Institute of Oncogenomics of Brazil.
This study was supported by the National Institutes of Health (NIH). Kalluri is a Champalimaud investigator funded by the Champalimaud metastasis programme. Cooke is funded by a Ruth Kirschstein Post-doctoral fellowship. LeBleu is funded by an NIH training grant in gastroenterology. Duncan is funded by an NIH training grant in cancer biology, an NIH supplemental grant to support diversity, and a United Negro College Fund-Merck Postdoctoral Science Research Fellowship. Sugimoto is funded by an NIH research training grant in cardiovascular medicine. O'Connell is funded by the Department of Defense Breast Cancer Predoctoral Traineeship Award.
Beth Israel Deaconess Medical Center is a patient care, teaching and research affiliate of Harvard Medical School and ranks third in National Institutes of Health funding among independent hospitals nationwide. BIDMC is a clinical partner of the Joslin Diabetes Center and a research partner of the Dana-Farber/Harvard Cancer Center. BIDMC is the official hospital of the Boston Red Sox. For more information, visit www.bidmc.org.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Non-invasive measurements of tricuspid valve anatomy can predict severity of valve leakagePublic release date: 18-Jan-2012 [ | E-mail | Share ]
Contact: Abby Robinson abby@innovate.gatech.edu 404-385-3364 Georgia Institute of Technology Research News
An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valves, which are complex structures that allow blood to flow from the heart's upper right chamber to the ventricle. If left untreated, severe leakage can affect an individual's quality of life and can even lead to death.
A new study finds that the anatomy of the heart's tricuspid valve can be used to predict the severity of leakage in the valve, which is a condition called tricuspid regurgitation. The study, conducted by researchers from the Georgia Institute of Technology and Emory University, found that pulmonary arterial pressure, the size of the valve opening and papillary muscle position measurements could be used to predict the severity of an individual's tricuspid regurgitation.
"By being able to identify and measure an individual's particular tricuspid valve anatomical features that we have shown are correlated with increased leakage, clinicians should be able to better target their repair efforts and create more durable repairs," said Ajit Yoganathan, Regents' professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.
The study was published in the January issue of the journal Circulation: Cardiovascular Imaging. Funding for this work was provided by the American Heart Association and a donation from Tom and Shirley Gurley.
Yoganathan and recent Coulter Department doctoral graduate Erin Spinner teamed with Stamatios Lerakis, a professor of medicine (cardiology), radiology and imaging sciences at Emory University, to non-invasively collect 3-D echocardiograms from 64 individuals who exhibited assorted grades of tricuspid leakage. Subjects included 20 individuals with "trace," 13 with "mild," 17 with "moderate" and 14 with "severe" tricuspid regurgitation. The subjects with "mild" to "severe" leakage exhibited a mix of isolated right, isolated left, and both right and left ventricle dilation.
From the 3-D echocardiography images of the heart they collected, the researchers measured (1) the area of the annulus, which is the fibrous ring that surrounds the tricuspid valve opening; (2) the distance between the annulus and the three right ventricle papillary muscles, which keep the valve shut when the ventricle contracts; and (3) the position of the papillary muscles with respect to the center of the annulus. The clinicians also measured pulmonary arterial pressure using standard clinical methods and assessed the grade of tricuspid regurgitation from "trace" to "severe" with color Doppler imaging.
In collaboration with Emir Veledar, an assistant professor and statistician in the Rollins School of Public Health at Emory University, the researchers found statistical differences between individuals with ventricular dilation and the control subjects in the parameters of pulmonary arterial pressure, annulus area and papillary muscle displacement. They also found that all three factors were correlated with the grade of tricuspid regurgitation.
"This study's use of advanced cardiovascular imaging, and more specifically 3-D echocardiography, provided new insight into the pathophysiology of tricuspid regurgitation and a good understanding as to why current surgical treatments for tricuspid regurgitation are not good enough," explained Lerakis. "I believe this study will change the focus and direction of future surgical therapies for tricuspid regurgitation only to make them better and more durable."
Based on the findings of this study, said Lerakis, future surgical therapies should not only be focused on the tricuspid annulus, but on the entire tricuspid valve apparatus, including the tricuspid valve papillary muscles and their three-dimensional location within the apparatus.
Individuals in the study with left ventricle dilation exhibited significant displacement of one of the papillary muscles and patients with both ventricles dilated had significant displacement of two papillary muscles. Subjects with right ventricle dilation showed significant displacement of all three papillary muscles.
The researchers also found that patients with a dilated right ventricle were more likely to have a dilated annulus and exhibited the highest pulmonary arterial pressures and highest levels of tricuspid regurgitation. However, not all patients with a dilated right ventricle had significant increases in annulus area, providing evidence that the right ventricle may become dilated without the annulus being affected.
"We think an increase in pulmonary arterial pressure caused geometric changes in the ventricle, which resulted in alterations to the annulus and papillary muscles," explained Yoganathan. "The combination of displacement of all three papillary muscles and annular dilatation may account for the patients with isolated right ventricle dilatation having the largest percentage of severe tricuspid regurgitation."
Knowing which parameters are responsible for significant tricuspid regurgitation and having a non-invasive imaging technique to measure these parameters should help clinicians target repairs to the specific cause of an individual's tricuspid leakage, according to Yoganathan.
In future studies, the researchers plan to study papillary muscle displacements in individuals with specific diseases to see if different disease manifestations exhibit different characteristics.
"Although it has long been accepted that pulmonary hypertension may result in tricuspid regurgitation, this study is one of the first to provide a clinical correlation between the two," said Yoganathan, who is also the Wallace H. Coulter Distinguished Faculty Chair in Biomedical Engineering. "We want to know whether treating an individual's pulmonary hypertension, and thus decreasing one's pulmonary arterial pressure, can reverse the geometric changes that are causing tricuspid regurgitation and return the annulus and papillary muscles to their original positions."
###
Emory University sonographers Jason Higginson, Maria Pernetz and Sharon Howell also contributed to the study.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
Non-invasive measurements of tricuspid valve anatomy can predict severity of valve leakagePublic release date: 18-Jan-2012 [ | E-mail | Share ]
Contact: Abby Robinson abby@innovate.gatech.edu 404-385-3364 Georgia Institute of Technology Research News
An estimated 1.6 million Americans suffer moderate to severe leakage through their tricuspid valves, which are complex structures that allow blood to flow from the heart's upper right chamber to the ventricle. If left untreated, severe leakage can affect an individual's quality of life and can even lead to death.
A new study finds that the anatomy of the heart's tricuspid valve can be used to predict the severity of leakage in the valve, which is a condition called tricuspid regurgitation. The study, conducted by researchers from the Georgia Institute of Technology and Emory University, found that pulmonary arterial pressure, the size of the valve opening and papillary muscle position measurements could be used to predict the severity of an individual's tricuspid regurgitation.
"By being able to identify and measure an individual's particular tricuspid valve anatomical features that we have shown are correlated with increased leakage, clinicians should be able to better target their repair efforts and create more durable repairs," said Ajit Yoganathan, Regents' professor in the Wallace H. Coulter Department of Biomedical Engineering at Georgia Tech and Emory University.
The study was published in the January issue of the journal Circulation: Cardiovascular Imaging. Funding for this work was provided by the American Heart Association and a donation from Tom and Shirley Gurley.
Yoganathan and recent Coulter Department doctoral graduate Erin Spinner teamed with Stamatios Lerakis, a professor of medicine (cardiology), radiology and imaging sciences at Emory University, to non-invasively collect 3-D echocardiograms from 64 individuals who exhibited assorted grades of tricuspid leakage. Subjects included 20 individuals with "trace," 13 with "mild," 17 with "moderate" and 14 with "severe" tricuspid regurgitation. The subjects with "mild" to "severe" leakage exhibited a mix of isolated right, isolated left, and both right and left ventricle dilation.
From the 3-D echocardiography images of the heart they collected, the researchers measured (1) the area of the annulus, which is the fibrous ring that surrounds the tricuspid valve opening; (2) the distance between the annulus and the three right ventricle papillary muscles, which keep the valve shut when the ventricle contracts; and (3) the position of the papillary muscles with respect to the center of the annulus. The clinicians also measured pulmonary arterial pressure using standard clinical methods and assessed the grade of tricuspid regurgitation from "trace" to "severe" with color Doppler imaging.
In collaboration with Emir Veledar, an assistant professor and statistician in the Rollins School of Public Health at Emory University, the researchers found statistical differences between individuals with ventricular dilation and the control subjects in the parameters of pulmonary arterial pressure, annulus area and papillary muscle displacement. They also found that all three factors were correlated with the grade of tricuspid regurgitation.
"This study's use of advanced cardiovascular imaging, and more specifically 3-D echocardiography, provided new insight into the pathophysiology of tricuspid regurgitation and a good understanding as to why current surgical treatments for tricuspid regurgitation are not good enough," explained Lerakis. "I believe this study will change the focus and direction of future surgical therapies for tricuspid regurgitation only to make them better and more durable."
Based on the findings of this study, said Lerakis, future surgical therapies should not only be focused on the tricuspid annulus, but on the entire tricuspid valve apparatus, including the tricuspid valve papillary muscles and their three-dimensional location within the apparatus.
Individuals in the study with left ventricle dilation exhibited significant displacement of one of the papillary muscles and patients with both ventricles dilated had significant displacement of two papillary muscles. Subjects with right ventricle dilation showed significant displacement of all three papillary muscles.
The researchers also found that patients with a dilated right ventricle were more likely to have a dilated annulus and exhibited the highest pulmonary arterial pressures and highest levels of tricuspid regurgitation. However, not all patients with a dilated right ventricle had significant increases in annulus area, providing evidence that the right ventricle may become dilated without the annulus being affected.
"We think an increase in pulmonary arterial pressure caused geometric changes in the ventricle, which resulted in alterations to the annulus and papillary muscles," explained Yoganathan. "The combination of displacement of all three papillary muscles and annular dilatation may account for the patients with isolated right ventricle dilatation having the largest percentage of severe tricuspid regurgitation."
Knowing which parameters are responsible for significant tricuspid regurgitation and having a non-invasive imaging technique to measure these parameters should help clinicians target repairs to the specific cause of an individual's tricuspid leakage, according to Yoganathan.
In future studies, the researchers plan to study papillary muscle displacements in individuals with specific diseases to see if different disease manifestations exhibit different characteristics.
"Although it has long been accepted that pulmonary hypertension may result in tricuspid regurgitation, this study is one of the first to provide a clinical correlation between the two," said Yoganathan, who is also the Wallace H. Coulter Distinguished Faculty Chair in Biomedical Engineering. "We want to know whether treating an individual's pulmonary hypertension, and thus decreasing one's pulmonary arterial pressure, can reverse the geometric changes that are causing tricuspid regurgitation and return the annulus and papillary muscles to their original positions."
###
Emory University sonographers Jason Higginson, Maria Pernetz and Sharon Howell also contributed to the study.
[ | E-mail | Share ]
?
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.
MANILA, Philippines ? The Philippine Senate has begun an impeachment trial of the Supreme Court chief justice, who has been accused of corruption and blocking the prosecution of detained former President Gloria Macapagal Arroyo.
Senate President Juan Ponce Enrile promised Monday an impartial and fair trial for Chief Justice Renato Corona. Corona was impeached by the House of Representatives last month on allegations that include a bias for Arroyo, who has been detained on electoral fraud charges.
Corona is attending the trial. He earlier declared in a speech before Supreme Court employees that he would fight to prove his innocence and defend the court's independence.
MONDAY, Jan. 16 (HealthDay News) -- Variations in a certain gene can make people more or less sensitive to the taste of fat and affect their risk for obesity, researchers report.
The team at the Washington University School of Medicine in St. Louis studied 21 obese people and found that those with a particular variant of the CD36 gene were far more sensitive to the taste of fat.
This is the first study to identify a receptor on human tongues that can taste fat. The finding was recently published in the Journal of Lipid Research.
"The ultimate goal is to understand how our perception of fat in food might influence what foods we eat and the quantities of fat that we consume," senior investigator Nada Abumrad, a professor of medicine and obesity research, said in a university news release.
"In this study, we've found one potential reason for individual variability in how people sense fat. It may be, as was shown recently, that as people consume more fat, they become less sensitive to it, requiring more intake for the same satisfaction. What we will need to determine in the future is whether our ability to detect fat in foods influences our fat intake, which clearly would have an impact on obesity," Abumrad noted.
Previous research found that rats and mice without a working CD36 gene no longer had a preference for fatty foods and that animals that can't make the CD36 protein have difficulty digesting fat.
It's believed that up to 20 percent of people have a CD36 gene variant that's associated with making significantly less CD36 protein. This, in turn, could make them less sensitive to the presence of fat in food, the researchers said.
More information
The U.S. National Institutes of Health has more about dietary fats.
ATHENS (Reuters) ? Germany is optimistic about the outcome of a bond swap deal aimed at slashing Greece's towering debt pile, Germany's foreign minister said during a visit to Athens Sunday which he said brought a message of solidarity.
Pressure is mounting on Athens to complete a deal with private bondholders to cut its debt to more sustainable levels and convince its international lenders to keep giving it the cash it needs. Without aid, Athens would default in March when it has to redeem 14.5 billion in bonds.
Foreign Minister Guido Westerwelle's visit came two days after talks on private sector debt modification broke down, pushing Athens closer to default.
"Discussions (on the bond swap) are difficult but with good faith they will reach a good result," Westerwelle said after a meeting with his Greek counterpart Stavros Dimas.
"It is very important that we give negotiations and packages a realistic chance," he said.
Germany has repeatedly urged Greece to meet the fiscal conditions set out by its lenders - the European Union and the International Monetary Fund - but Westerwelle said Germany would stand ready to help.
"Germany will help so that there will be better days ahead," Westerwelle said, speaking through an interpreter. "My visit brings a message of solidarity."
Friday, Standard & Poor's downgraded the credit ratings of nine euro zone countries, stripping France and Austria of their coveted triple-A status but not EU paymaster Germany.
"It is time for Europe to prove it is able to tackle the issue of credit ratings agencies," Westerwelle said.
(Reporting by George Georgiopoulos; Editing by Karolina Tagaris and Peter Graff)